首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1542932

全球排卵測試套件市場 - 2024-2031

Global Ovulation Testing Kits Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

報告概述

全球排卵測試套件市場在 2023 年達到 31.5 億美元，預計到 2031 年將達到 52.9 億美元，2024-2031 年預測期間複合年成長率為 6.7%。

排卵測試套件也稱為排卵預測測試 (OPK)，是一種家用設備，旨在檢測女性尿液中是否存在黃體生成素 (LH)。 LH 水平在排卵前不久飆升，標誌著女性試圖懷孕的最容易受孕的時間。透過識別 LH 激增，這些套件可協助使用者確定理想的性交時間，以提高受孕的可能性。

排卵是月經週期中最容易受孕的時期，LH 激增通常會在卵子從卵巢釋放前 1-2 天發生。黃體生成素 (LH) 排卵檢測試劑盒是一種側流免疫測定法。它們需要尿液樣本，有三種形式：試紙、盒式和中流式。

市場動態：

司機

生育障礙發病率上升和技術進步

全球排卵測試套件市場的需求是由多種因素所驅動的。多囊性卵巢症候群 (PCOS) 等生育障礙的發生率不斷上升，導致對排卵檢測試劑盒的需求增加。這些套件可以幫助患有此類疾病的女性有效追蹤她們的月經週期。

多囊性卵巢症候群 (PCOS) 是一種常見的內分泌疾病，影響相當多的育齡婦女，全球盛行率在 5% 至 20% 之間。這種情況的特徵是荷爾蒙失衡，可能導致各種症狀，例如月經週期不規則、不排卵（不排卵）和多囊性卵巢。這些症狀可能導致不孕，使多囊性卵巢症候群成為女性生殖挑戰的主要原因之一。

測試技術的不斷創新，特別是連接到智慧型手機應用程式的數位排卵套件的開發，正在顯著改善追蹤生育能力的用戶體驗。數位排卵試劑盒通常利用先進的演算法和技術來提供更精確的荷爾蒙水平讀數，特別是在排卵前激增的黃體生成素 (LH)。例如，Premom 定量排卵測試等套件可以量化 LH 水平並以清晰的數位格式呈現，讓使用者更了解自己的荷爾蒙波動。這種高精確度（通常約為 97%）對於月經週期不規則或多囊性卵巢症候群 (PCOS) 等疾病的女性特別有益。

此外，併購、金融投資和關鍵開發等關鍵參與者策略將推動該市場的成長。例如，2022年3月，Ro透過收購Dadi（專門從事男性生育和精子檢測的公司）而引起關注，作為其向生育服務策略擴張的一部分。此次收購旨在增強 Ro 在生育領域的產品和服務，使該公司能夠向客戶提供更全面的產品和服務。

此外，2023 年 11 月，醫療科技新創公司 Inito 獲得了由 Fireside Ventures 領投的 600 萬美元 A 輪融資，Inito 是一家幫助女性在家中快速追蹤生育激素的醫療技術新創公司。該公司的生育監測儀和套件只需 10 分鐘即可在智慧型手機上為用戶提供易於理解的診斷結果。

此外，政府措施（例如意識計劃和主要參與者對生殖健康的認可）也推動了該市場的成長。例如，2023 年 11 月，Premom Easy@Home 排卵試紙被著名網站 The Bump 在其年度 Best of The Bump Awards 中評為 2023 年最佳排卵試紙。該活動涉及針對新父母和有抱負的父母對各種嬰兒和懷孕產品進行徹底測試。 Easy@Home 排卵試紙在準確性、用戶友善性和成本效益方面表現出色，使其成為生殖健康市場的領先選擇。

限制

套件成本高昂、缺乏熟練的專業人員、人們的意識有限以及資料隱私問題等因素預計將阻礙市場的發展。

細分市場分析

全球排卵測試套件市場根據產品類型、分銷管道和地區進行細分。

尿液排卵測試部分約佔全球排卵測試套件市場佔有率的63.5%

尿液排卵測試預計將在預測期內佔據最大的市場佔有率。尿液排卵測試因其在檢測排卵前黃體生成素 (LH) 激增方面的有效性而得到認可。這種準確度對於試圖懷孕的女性至關重要，因為它使她們能夠確定她們的最佳受孕日。

尿液排卵測試套件專為方便家庭使用而設計，提高了女性的可及性。它們有多種格式，包括試紙、試紙盒和中游測試，使用戶能夠選擇最適合自己喜好和需求的選項。

此外，該行業的主要參與者推出的創新產品和技術進步將推動該市場的成長。例如，2022 年 9 月，新加坡醫療設備和電器製造商 BUZUD 宣布推出 LH 排卵快速檢測試劑盒用於自我檢測。該測試旨在檢測尿液中的黃體生成素 (LH)，該激素在排卵前激增，幫助女性確定她們最容易受孕的日子。 BUZUD LH 排卵快速測試套件的準確度超過 99%，為那些希望懷孕或更好地了解月經週期的人們提供了可靠的解決方案。這些產品在新加坡的推出標誌著女性健康和生育追蹤領域的重要發展。

同樣，2023 年 5 月，消費品公司 Fridababy, LLC 宣布推出新的生育產品系列。該系列產品包括排卵預測測試、家庭授精套件以及用於追蹤排卵和懷孕測試的套件。排卵預測測試的設計價格實惠且方便用戶使用。

此外，合作夥伴關係和協作等關鍵參與者策略將推動該細分市場在該市場的成長。例如，從 2023 年 7 月開始，希望組建或擴大家庭的女性現在可以透過 questhealth.com 取得 Proov 確認 PdG 家庭收集套件以進行生育力評估。該套件是 Quest Diagnostics 的消費者發起的測試部門與 Proov（專門從事家庭生育和荷爾蒙測試的公司）合作的成果。 Proov 確認 PdG 測試因其是第一個也是唯一一個經 FDA 批准的家庭測試套件而聞名，旨在透過測量黃體酮代謝物 (PdG) 來確認成功排卵。

市場地域佔有率

北美約佔全球排卵檢測試劑盒市場佔有率的43.5%

由於荷爾蒙失衡和生活方式因素等生育相關挑戰的增加，預計北美地區將在預測期內佔據最大的市場佔有率，這加劇了對可靠排卵監測工具的需求。此外，多囊性卵巢症候群（PCOS）的高發生率影響了相當多的育齡婦女，這也大大促進了需求的增加。

藍牙連接和智慧倒數功能等先進功能的引入推動了對排卵測試套件不斷成長的需求。女性對生殖健康和生育管理的認知不斷提高，推動了排卵檢測試劑的使用。

此外，大量關鍵參與者的存在、產品發布、合作夥伴關係和協作將推動該地區的市場成長。例如，2023 年 8 月，在美國，家庭懷孕和生育測試領域的領先品牌可麗藍 (Clearblue) 正在擴展到更年期類別，推出了新的可麗藍 (Clearblue) 更年期階段指示器。這個突破性的產品是第一個也是唯一一個可以透過結合尿液 FSH 測量值與年齡和月經週期歷史來確定女性可能的更年期階段的家庭測試。

可麗藍旨在透過為女性提供追蹤更年期進展的工具並與她們的醫療保健提供者進行知情對話來賦予女性權力。 Clearblue 更年期階段指示器將測試結果安全地儲存在免費的更年期階段 - Clearblue me 應用程式上。透過每隔一天進行五次尿液 FSH 測試，該應用程式可以確定女性可能的更年期階段。

同樣，2022 年，領先的數位排卵測試套件生產商 Sugentech 與 CGETC, Inc.（一家專門從事消費者履行和行銷服務的美國公司）建立了策略合作夥伴關係。市面上有各種配備先進功能的數位設備，例如藍牙連接和智慧倒數功能。該領域的知名品牌包括 Clearblue、First Response 和 EPT

Ovulation testing kits, also referred to as ovulation predictor tests (OPKs), are at-home devices designed to detect the presence of luteinizing hormone (LH) in a woman's urine. LH levels spike shortly before ovulation, marking the most fertile time for women attempting to become pregnant. By identifying this LH surge, these kits assist users in determining the ideal time for sexual intercourse to enhance the likelihood of conception.

Ovulation is the most fertile period of the menstrual cycle, and an LH surge will often occur 1-2 days before an egg is released from the ovary. The luteinizing hormone (LH) ovulation test kit is a lateral flow immunoassay. They require a urine sample and are available in three forms: test strip, cassette, and midstream.

Market Dynamics: Drivers

Rising incidence of fertility disorders and technological advancements

The demand for the global ovulation testing kits market is driven by multiple factors. Rising incidence of fertility disorders such as conditions such as polycystic ovary syndrome (PCOS) are becoming more prevalent, leading to a higher demand for ovulation testing kits. These kits help women with such disorders track their cycles effectively.

Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder that impacts a considerable number of women of reproductive age, with global prevalence rates ranging from 5% to 20%. This condition is marked by hormonal imbalances that can result in various symptoms, such as irregular menstrual cycles, anovulation (the failure to ovulate), and the presence of polycystic ovaries. These symptoms can lead to infertility, positioning PCOS as one of the primary causes of reproductive challenges among women.

Continuous innovations in testing technology, particularly the development of digital ovulation kits that connect to smartphone applications, are significantly improving the user experience for those tracking fertility. Digital ovulation kits often utilize advanced algorithms and technology to provide more precise readings of hormone levels, specifically luteinizing hormone (LH), which surges before ovulation. For instance, kits like the Premom Quantitative Ovulation Test can quantify LH levels and present them in a clear, numerical format, allowing users to understand their hormonal fluctuations better. This high accuracy-often around 97%-is particularly beneficial for women with irregular cycles or conditions like polycystic ovary syndrome (PCOS).

Moreover, key player strategies such as mergers & acquisitions, financial investments, and key developments would propel this market growth. For instance, in March 2022, Ro gained attention by acquiring Dadi, a company specializing in male fertility and sperm testing, as part of its strategic expansion into fertility services. This acquisition aims to enhance Ro's offerings in the fertility sector, enabling the company to provide a more comprehensive array of products and services to its clients.

Also, in November 2023, Inito, a medical technology startup that enables women to quickly track fertility hormones at home, secured $6 million in Series A funding led by Fireside Ventures. The company's fertility monitor and kit provide users with easy-to-understand diagnostic results on their smartphones in just 10 minutes.

In addition, government initiatives such as awareness programs and key players' recognition in reproductive health drive this market growth. For instance, in November 2023, Premom Easy@Home ovulation test strips were recognized as the 2023 Best Ovulation Test Strips by the reputable site The Bump during its annual Best of The Bump Awards. This event involves thorough testing of various baby and pregnancy products aimed at new and aspiring parents. The Easy@Home ovulation strips excelled in accuracy, user-friendliness, and cost-effectiveness, establishing them as a leading choice in the reproductive health market.

Restraints

Factors such as the high costs of kits, lack of skilled professionals, limited awareness among people, and Data privacy concerns are expected to hamper the market.

Market Segment Analysis

The global ovulation testing kits market is segmented based on product type, distribution channels, and region.

The urine ovulation tests segment accounted for approximately 63.5% of the global ovulation testing kits market share

The urine ovulation tests segment is expected to hold the largest market share over the forecast period. Urine ovulation tests are recognized for their effectiveness in detecting the surge of luteinizing hormone (LH) that happens right before ovulation. This level of accuracy is essential for women attempting to conceive, as it enables them to pinpoint their peak fertile days.

Urine ovulation test kits are designed for convenient at-home use, enhancing their accessibility for women. They are available in diverse formats, including test strips, cassettes, and midstream tests, enabling users to select the option that best fits their preferences and needs.

Moreover, key players in the industry have innovative launches and technological advancements that would propel this market growth. For instance, in September 2022, BUZUD, a Singapore-based manufacturer of medical devices and appliances, announced the launch of their LH Ovulation Rapid Test Kits for self-testing. The test is designed to detect luteinizing hormone (LH) in urine, which surges before ovulation, helping women identify their most fertile days. With over 99% accuracy, the BUZUD LH Ovulation Rapid Test Kits offer a reliable solution for those looking to conceive or better understand their menstrual cycles. The launch of these products in Singapore marks an important development in women's health and fertility tracking.

Similarly, in May 2023, Fridababy, LLC, a consumer goods company, announced the introduction of a new line of fertility products. This line features an ovulation prediction test, an at-home insemination kit, and a set for tracking ovulation and pregnancy tests. The ovulation prediction test is designed to be affordable and user-friendly.

In addition, key player strategies such as partnerships & collaboration would propel this segment's growth in this market. For instance, in July 2023, Women looking to begin or expand their families can now obtain the Proov Confirm PdG home collection kit for fertility assessment through questhealth.com. This kit is a result of a collaboration between Quest Diagnostics' consumer-initiated testing division and Proov, a company specializing in at-home fertility and hormone tests. The Proov Confirm PdG test is notable for being the first and only FDA-cleared home test kit designed to confirm successful ovulation by measuring the progesterone metabolite (PdG).

Market Geographical Share

North America accounted for approximately 43.5% of the global ovulation testing kits market share

North America region is expected to hold the largest market share over the forecast period owing to the rise in fertility-related challenges, such as hormonal imbalances and lifestyle factors, which have intensified the demand for reliable ovulation monitoring tools. In addition, the high incidence of Polycystic Ovary Syndrome (PCOS), which impacts a considerable number of women of reproductive age, significantly contributes to this increased demand.

The rising demand for ovulation test kits is fueled by the introduction of advanced features like Bluetooth connectivity and smart countdown functions. The rising awareness of reproductive health and fertility management among women is fueling the uptake of ovulation testing kits.

Moreover, a major number of key player's presence, product launches, partnerships & collaborations would drive this market growth in this region. For instance, in August 2023, in the U.S., Clearblue the leading brand in home pregnancy and fertility tests, is expanding into the menopause category with the launch of its new Clearblue Menopause Stage Indicator. This groundbreaking product is the first and only at-home test that can determine a woman's likely menopause stage by combining her urine FSH measurements with her age and cycle history.

Clearblue aims to empower women by providing them with a tool to track their menopause progression and have informed conversations with their healthcare providers. The Clearblue Menopause Stage Indicator securely stores test results on the free Menopause Stage -Clearblue me app. By taking five urine FSH tests every other day, the app can determine a woman's likely menopause stage.

Similarly, in 2022, Sugentech, a leading producer of digital ovulation test kits, formed a strategic partnership with CGETC, Inc., a U.S.-based company that specializes in consumer fulfillment and marketing services. The market features various digital devices equipped with advanced functionalities such as Bluetooth connectivity and smart countdown features. Prominent brands in this sector include Clearblue, First Response, and E.P.T.

Market Segmentation

By Product Type

Urine Ovulation Tests
- Ovulation Test Strips
- Ovulation Test Cassette (CE)
- Ovulation Midstream Tests
Saliva Ovulation Tests
Digital Ovulation Kit

By Distribution Channels

E-Commerce
Online & Retail Pharmacies
Hypermarkets & Supermarkets

By Region

North America
- The U.S.
- Canada
- Mexico
Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
South America
- Brazil
- Argentina
- The rest of South America
Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Middle East and Africa

Market Competitive Landscape

The major global players in the ovulation testing kits market include AdvaCare Pharma, Swiss Precision Diagnostics GmbH, Proov, PREGMATE, Easy@Home Fertility, Fairhaven Health, Ro, Piramal Pharma Ltd., Wondfo, and Accuquik Test Kits among others.

Key Developments

In June 2024, Mankind Pharma launched a new line of pregnancy care products in the Southern market, featuring celebrity Kajal Agarwal. The brand aims to expand its presence by offering essential pregnancy items, having experienced significant growth in regions like Karnataka. This new product line includes a comprehensive range of six curated items designed for the pre-, during-, and post-pregnancy phases, all supported by extensive research. The preconception phase includes the Ova News Ovulation Detection Kit which helps identify the five most fertile days in a woman's cycle, enhancing the chances of conception.

Why Purchase the Report?

To visualize the global ovulation testing kits market segmentation based on product type, distribution channels, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the ovulation testing kits market with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.

The global ovulation testing kits market report would provide approximately 54 tables, 42 figures, and 182 pages.

Target Audience 2024

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Distribution Channels
3.3. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising Incidence of Fertility Disorders and Technological Advancements
- 4.1.2. Restraints
  - 4.1.2.1. High Costs of kits
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Urine Ovulation Tests *
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.2.3. Ovulation Test Strips
- 6.2.4. Ovulation Test Cassette (CE)
- 6.2.5. Ovulation Midstream Tests
6.3. Saliva Ovulation Tests
6.4. Digital Ovulation Kit

7. By Distribution Channels

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 7.1.2. Market Attractiveness Index, By Distribution Channels
7.2. E-Commerce*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Online & Retail Pharmacies
7.4. Hypermarkets & Supermarkets

8. By Region

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 8.1.2. Market Attractiveness Index, By Region
8.2. North America
- 8.2.1. Introduction
- 8.2.2. Key Region-Specific Dynamics
- 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.2.5.1. The U.S.
  - 8.2.5.2. Canada
  - 8.2.5.3. Mexico
8.3. Europe
- 8.3.1. Introduction
- 8.3.2. Key Region-Specific Dynamics
- 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.3.5.1. Germany
  - 8.3.5.2. U.K.
  - 8.3.5.3. France
  - 8.3.5.4. Spain
  - 8.3.5.5. Italy
  - 8.3.5.6. Rest of Europe
8.4. South America
- 8.4.1. Introduction
- 8.4.2. Key Region-Specific Dynamics
- 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.4.6.1. Brazil
  - 8.4.6.2. Argentina
  - 8.4.6.3. Rest of South America
8.5. Asia-Pacific
- 8.5.1. Introduction
- 8.5.2. Key Region-Specific Dynamics
- 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.5.5.1. China
  - 8.5.5.2. India
  - 8.5.5.3. Japan
  - 8.5.5.4. South Korea
  - 8.5.5.5. Rest of Asia-Pacific
8.6. Middle East and Africa
- 8.6.1. Introduction
- 8.6.2. Key Region-Specific Dynamics
- 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels

9. Competitive Landscape

9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis

10. Company Profiles

10.1. AdvaCare Pharma *
- 10.1.1. Company Overview
- 10.1.2. Product Portfolio and Description
- 10.1.3. Financial Overview
- 10.1.4. Key Developments
10.2. Swiss Precision Diagnostics GmbH
10.3. Proov
10.4. PREGMATE
10.5. Easy@Home Fertility
10.6. Fairhaven Health
10.7. Ro
10.8. Piramal Pharma Ltd.
10.9. Wondfo
10.10. Accuquik Test Kits (*LIST NOT EXHAUSTIVE)